AstraZeneca completes acquisition of Amolyt Pharma

LYON, France and CAMBRIDGE, Mass., July 15, 2024 (GLOBE NEWSWIRE) — Amolyt Pharma, a global clinical-stage biopharmaceutical company focused on developing therapeutic peptides for rare endocrine and related diseases, today announced that its previously announced acquisition by global pharmaceutical company AstraZeneca has been completed.

Acquisition strengthens Alexion’s late-stage development of AstraZeneca Rare Disease and expands bone metabolism franchise with significant addition of enebopatide (AZP-3601), a Phase III investigational peptide therapeutic with a novel mechanism of action designed to address key therapeutic targets in hypoparathyroidism. In patients with hypoparathyroidism, deficient production of parathyroid hormone (PTH) results in significant calcium and phosphate dysregulation, which can lead to life-changing symptoms and complications, including chronic kidney disease. This program, along with Amolyt’s talented team, expertise and earlier development phase, will enable Alexion’s expansion into rare endocrinology.

Under the terms of the definitive agreement, AstraZeneca acquired all of the outstanding shares of Amolyt Pharma for an aggregate consideration of up to $1.05 billion on a cash and debt-free basis. This includes $800 million upfront at closing, plus the right of Amolyt Pharma shareholders to receive an additional contingent payment of $250 million payable upon achievement of certain regulatory milestones.

About Amolyt Pharma

Amolyt Pharma, a clinical-stage biotechnology company, is building on its team’s established expertise to deliver life-changing therapies to patients with rare endocrine and related diseases. Its development portfolio includes eneboparatide (AZP-3601), a long-acting PTH1 receptor agonist as a potential treatment for hypoparathyroidism, and AZP-3813, a growth hormone peptide receptor antagonist as a potential treatment for acromegaly. To learn more, visit https://amolytpharma.com/ or follow us on Twitter and LinkedIn.

Contact Amolyte:
Patrick Loustau
Business Director
[email protected]

Media inquiries:
Jordyn Temperato
LifeSci Communications
[email protected]